论文部分内容阅读
为探讨抑癌基因P16蛋白在膀胱移行细胞癌中表达的临床意义，应用免疫组化法（ABC法）对69例膀胱移行细胞癌中抑癌基因P16蛋白产物进行检测。结果：69例膀胱癌标本中37例检测P16蛋白阳性（53．62％）。P16蛋白阳性率在Ⅰ、Ⅱ和Ⅲ级肿瘤中分别为69．57％（16／23）、56．25％（18／32）和21．43％（3／14）。在Tis～T1期和T2～T4期肿瘤中分别为70．59％（24／34）和37．14％（13／35）。P16蛋白表达阳性率随着膀优癌病理分级、临床分期的上升而逐渐下降。其阳性率在肿瘤的病理分级、临床分期和预后等方面均有显著性差异（P＜0．05）。认为P16蛋白在抑制膀胱肿瘤的发生、发展中起着重要作用，可作为膀胱癌的生物学瘤标。
To investigate the clinical significance of the expression of the tumor suppressor gene P16 in bladder transitional cell carcinoma, the expression of the tumor suppressor gene P16 in 69 cases of transitional cell carcinoma of the bladder was detected by immunohistochemistry (ABC method). Results: Of 69 bladder cancer samples, 37 cases were positive for P16 protein (53.62%). The positive rate of P16 protein was 69.57% (16/23), 56.25% (18/32) and 21.43% (3/14) in grade I, II and III tumors, respectively. 70.59% (24/34) and 37.14% (13/35) in Tis ~ T1 and T2 ~ T4 tumors, respectively. P16 protein expression positive rate with the bladder cancer grade, clinical stage and gradually decreased. The positive rate in tumor pathological grading, clinical stage and prognosis have significant differences (P <0.05). P16 protein is considered in the inhibition of the occurrence and development of bladder cancer plays an important role, as a biological marker of bladder cancer.